NASDAQ$STOK

Stoke Therapeutics Inc · Q2 2022 earnings

Q2 2022 earnings · · Investor relations

Headline financials

Total Revenue

$3.23M

No prior period
EPS (adj)

-$0.63

Previous: -$0.60-5.0%
Capital Expenditures

-$1.52M

Previous: $520K-392.9%
Free Cash Flow

-$26.2M

Previous: -$16.4M-60.1%
Net Income

-$24.7M

Previous: -$22M-12.2%
Operating Income

-$25.2M

Previous: -$22M-14.6%
Gross Profit

$3.23M

No prior period
Cash & Equivalents

$67.8M

Previous: $169M-59.9%
Total Assets

$301M

Previous: $264M+14.0%
Stock-Based Comp

$6.16M

Previous: $4.45M+38.4%

Revenue & EPS history

Stoke Therapeutics · Revenue · Quarterly

$3.23M

Q2 2022
Beat estimate in 11 of 15 quarters(73%)
ActualEstimate

Revenue by segment

Stoke Therapeutics · $3.27M total across 1 segment · Q4 2022

  • Acadia Pharm.
    $3.27M

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2022

Historical avgQ2 2022

+4.2%

Avg return

Earnings day

+4.9%

Avg return

5 days after

+3.1%

Avg return

30 days after

48%

13 / 27 earnings

Positive

+63.3%

Q4 2023

Best reaction

-20.0%

Q3 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-1.5%-2.6%-9.8%
Q4 2025-2.8%-1.3%+4.1%
Q3 2025-10.1%-11.7%+21.8%
Q1 2025+1.2%-1.6%+19.7%
Q4 2024-1.4%-9.4%-14.6%
Q3 2024+1.1%+6.0%-4.0%
Q2 2024-0.6%+1.5%+3.3%
Q1 2024-0.7%-4.5%+36.5%
Q4 2023+63.3%+114.3%+85.1%
Q3 2023+7.0%-1.2%+6.7%
Q2 2023-9.3%-11.1%-13.4%
Q1 2023+25.9%+28.1%+28.2%
Q4 2022+4.5%-1.0%-10.1%
Q3 2022-20.0%-35.9%-32.9%
Q2 2022+31.7%+28.6%-10.8%
Q1 2022+2.0%+17.3%+0.6%
Q4 2021-1.6%-2.1%+9.8%
Q3 2021+3.0%+9.4%-20.2%
Q2 2021-1.4%-2.4%-1.6%
Q1 2021+11.3%+9.9%+26.6%
Q4 2020+6.8%+1.5%-30.2%
Q3 2020-0.5%-7.8%+14.6%
Q2 2020+4.7%+8.5%+18.6%
Q1 2020+15.3%+18.9%-6.0%
Q4 2019-3.9%-2.3%-6.5%
Q3 2019-11.1%-21.7%-20.0%
Q2 2019+0.0%+5.3%-11.4%
Q1 2019
Q4 2018
Q3 2018
Q2 2018
Q1 2018

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro